Hong Kong stock movement | China Hui Biologicals-B (02627.HK) rises more than 5% as trivalent and quadrivalent influenza virus subunit vaccines enter Phase I clinical trial stage.

According to the Securities Times app, China Resources Pharmaceutical Group-Class B (02627.HK) rose more than 5%, as of the time of publication, it rose by 5.12% to HK$42.68, with a turnover of HK$8.3148 million.